New Targeted Therapy Shows Promise Against Mpox (Monkeypox) Virus Through Enhanced Immune Response
Nikhil Prasad Fact checked by:Thailand Medical News Team Nov 02, 2024 1 month, 3 days, 19 hours, 45 minutes ago
Medical News: Researchers Uncover Key Antiviral Mechanism
In an exciting new development, scientists from various esteemed institutions have discovered a promising new approach to fighting the monkeypox virus (MPXV). The breakthrough, spearheaded by researchers from the Changchun Institute of Applied Chemistry at the Chinese Academy of Sciences-China, the University of Science and Technology of China, the National Institute for Viral Disease Control and Prevention at the Chinese Center for Disease Control and Prevention, and the University of Warwick in the UK, focuses on a unique molecule that enhances immune response against MPXV by targeting specific RNA structures.
New Targeted Therapy Shows Promise Against Mpox (Monkeypox) Virus
Through Enhanced Immune Response
Monkeypox, or MPXV, which belongs to the Orthopoxvirus family, has posed public health challenges due to its infection rate, immune evasion, and limited treatment options. While vaccines for smallpox have been used to combat this virus, researchers have been on the lookout for more specialized antiviral strategies.
This
Medical News report delves into the study’s key findings, shedding light on the immune-enhancing mechanisms of a metallo-supramolecular complex, named MH3 Λ, which holds potential as a targeted antiviral therapy against MPXV.
Discovery of the RNA Structure Target
The study identified a distinct RNA structure, known as a G-quadruplex (G4), in the MPXV genome. G4s are unique arrangements within RNA that can influence virus behavior, including how it replicates and evades the immune system. By examining RNA within MPXV, the researchers uncovered that a stable G4 exists in the MPXV A5L gene, which produces a protein central to the virus’s life cycle and immune activation.
The researchers developed a specific metal-based compound, MH3 Λ, that can precisely bind to this G4 structure in MPXV RNA. Unlike many other antiviral agents, MH3 Λ works by stabilizing this G4 structure, thereby enhancing the stability of the mRNA and boosting the immune response. Their findings indicate that targeting this G4 with MH3 Λ could effectively disrupt the virus’s ability to evade immunity, making it harder for the virus to survive.
Mechanism of Action of MH3 Λ
The MH3 Λ complex is designed to be selective, binding strongly to the G4 in the virus's RNA without affecting the host's cellular structures. By binding to the MPXV G4 structure, MH3 Λ acts as a stabilizer. The stability of the RNA-G4 complex increases, which in turn raises the expression levels of a 39-kDa core protein encoded by the A5L gene in MPXV. This protein has a significant role in the immune response, and its enhanced expression could help the body mount a more effective defense against MPXV.
Furthermore, the team examined how MH3 Λ’s interaction with G4 affected the virus’s life cycle. They
observed that this stabilizing effect prevents the virus from replicating as efficiently, which ultimately leads to a reduction in viral activity. In contrast, when the RNA-G4 structure was destabilized using a specific protein called DHX36, the virus was able to evade immune detection more effectively, reducing the immune response and enhancing virus survival. This discovery points to the importance of the G4 structure in MPXV's survival and sheds light on why targeting it could be a game-changer.
Enhanced Protein Expression and Immune Response
The study showed that MH3 Λ’s binding led to significant improvements in the production of the core protein associated with the A5L gene. Through a series of laboratory tests, the researchers demonstrated that by increasing the expression of this protein, the MH3 Λ complex stimulates a stronger immune response, effectively reducing the virus's ability to multiply.
To assess the effect of MH3 Λ, scientists measured the immune response indicators in cells treated with the compound and found heightened levels of cytokines like IL-6 and TNF-α. These proteins, known for their role in immunity, were significantly more abundant when MH3 Λ was applied, compared to untreated cells. This response, combined with the reduced viral load, shows that MH3 Λ does more than merely target the virus directly; it essentially enhances the body’s own defense mechanisms.
Testing MH3 Λ's Specificity
Given the complexity of human biology and the existence of various G4s across the genome, a major concern was the compound's specificity. The team conducted extensive tests to ensure that MH3 Λ selectively binds to the MPXV RNA G4 and does not target other similar structures in the human genome. Through fluorescence resonance energy transfer (FRET) assays, they confirmed that MH3 Λ has little to no binding effect on human DNA G4 structures. This specificity reduces the chances of unwanted side effects, which is a crucial step forward for using MH3 Λ as a therapeutic compound.
Conclusions and Future Directions
The results from this groundbreaking study offer a promising new perspective on how to tackle MPXV. By focusing on the virus's unique RNA structure, the researchers were able to exploit a weakness that not only inhibits viral replication but also enhances the immune response. This dual approach could lead to significant advancements in MPXV treatment and potentially extend to other viruses with similar structures.
As monkeypox continues to affect various regions worldwide, MH3 Λ’s success in targeting MPXV G4 could pave the way for more specific antiviral treatments, especially for other poxviruses. The researchers are optimistic about the therapeutic potential of MH3 Λ, but they acknowledge that further studies and clinical trials are necessary to evaluate its efficacy and safety fully.
In conclusion, this study highlights the novel antiviral potential of the MH3 Λ metallo-supramolecular complex in targeting the G4 structure of MPXV. By bolstering the immune response and interfering with the virus’s replication process, MH3 Λ offers a new way to combat MPXV that may overcome the limitations of current antiviral treatments. The implications of these findings extend beyond monkeypox, suggesting that similar approaches could be applied to other viruses where G4 structures play a vital role.
The study findings were published in the peer-reviewed journal: National Science Review.
https://academic.oup.com/nsr/advance-article/doi/10.1093/nsr/nwae388/7854301
For the latest Mpox News, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/news/gene-discoveries-shed-light-on-mpox-virus-and-digestive-issues
https://www.thailandmedical.news/news/ceo-of-roche-warns-that-lots-of-mpox-cases-in-europe-are-not-being-reported
https://www.thailandmedical.news/articles/monkeypox